◂ Announcements

Oct 27, 2022ACQUISITIONUnited States

Geistlich Pharma North America acquires Lynch Biologics

Geistlich Pharma North America acquired Lynch Biologics, developer of GEM 21S, a recombinant growth factor product for oral regenerative surgery. The acquisition strengthens Geistlich's regenerative product portfolio.

Status

Completed

ProductsGEM 21Srecombinant growth factor product

CompaniesGeistlich Pharma North America acquirer Lynch Biologics target

Sectors#Medical Devices

“We're delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch.”biospace.com

1 source
biospace.comGeistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering companyHeather McKenzieOct 27, 2022

Summarized from public sources; check the original articles before acting on it.

Similar announcements

Nov 6, 2026ACQUISITIONMinnesota, United States
Confluent Medical Technologies acquires Northern Nitinol
Confluent Medical Technologies acquirer Northern Nitinol target globenewswire.com
Nov 6, 2026ACQUISITIONUnited States$9.90B
Danaher to acquire Masimo for $9.9 billion
Danaher acquirer Masimo target mdtvnow.com endata.com
Nov 5, 2026ACQUISITIONUnited States
Curewell Capital to acquire majority stake in ECA Medical
Curewell Capital acquirer ECA Medical target businesswire.com
Nov 5, 2026ACQUISITIONUnited States$538.0M
ZOLL Medical to acquire Itamar Medical for $538M
Asahi Kasei investor ZOLL Medical Corporation acquirer forpressrelease.com
Nov 4, 2026ACQUISITIONPlano, Texas, United States$2.25M
OSTEONIC acquires controlling stake in FoxEyes for 3 billion won
OSTEONIC FoxEyes target en.edaily.co.kr
Nov 3, 2026ACQUISITIONDeerfield, Illinois, United States
Vantive to divest majority of hemodialysis assets to Rockwell Medical
Vantive Rockwell Medical acquirer prnewswire.com

Loading…